1. Introduction {#sec1}
===============

It is estimated that over 850,000 people live with dementia in the UK alone and this figure is predicted to rise to over 2 million in the next 50 years. Research into new therapies and development of new drugs to stop or slow the progression of neurodegeneration is thus a major priority in health care. Development of treatment has been confounded in the past by difficulties in identifying the correct patients for new drug trials as it can be difficult clinically to distinguish between some forms as dementia such as Alzheimer\'s disease (AD) and frontotemporal dementia (FTD). Differential diagnosis between AD and FTD may be challenging as AD may manifest with behavioral disturbances (the "frontal variant" ([@bib9])) whereas, on the other side, memory disturbances may manifest in FTD, particularly in carriers *of GRN* and chromosome 9 open reading frame (*C9orf72)* mutations ([@bib11], [@bib30]). Cerebrospinal fluid (CSF) biomarkers amyloid beta 1-42 (Aβ), total tau (tau), and Tau phosphorylated at position 181 (Ptau) have a good accuracy in predicting AD ([@bib26]). In clinical practice, this analysis helps to rule out AD, but apparently normal results cannot exclude FTD, as no specific biomarkers are available for this disease. Moreover, tau may be altered in FTD (as well as in many other neurodegenerative conditions), but surprisingly values are often normal in genetic forms, despite evidence of clinical deterioration ([@bib4]). It is also possible that the CSF total- and phospho-tau (t-tau and p-tau, respectively) increase in AD is not a direct effect of tau pathology and neurodegeneration but rather reflects increased tau secretion from AD-affected neurons, as suggested in both animal studies ([@bib18]) and a recent tau kinetics study in man ([@bib33]). Further biomarkers are still needed as there is growing consensus that multiple biomarker panels may be the way forward in discriminating a molecular signature for individual dementias and their subtypes ([@bib4], [@bib26]). Targeted proteomics using multiple reaction monitoring liquid chromatography tandem mass spectrometry (MRM LC-MS/MS) is a useful technique in streamlining biomarker development. It does not require antibodies and can assay multiple proteins in a sample. Once a method is developed, it is capable of performing high-throughput analysis of multiple samples thereby enabling assessment of candidate markers. We have applied a previously described targeted proteomics platform of multiple markers of neurodegeneration in CSF from patients ([@bib12], [@bib15], [@bib28]). We describe the use of this assay to analyze multiple biomarkers of neurodegeneration in the CSF from patients with AD, sporadic FTD, and 2 forms of genetic FTD (patients with mutations in *GRN* or *C9orf72*). We have looked for proteins that show a change between the 2 different dementias AD and FTD and also an analysis looking at proteins that show changes between sporadic and genetic subtypes of FTD. Looking at the differences between the different FTD groups will hopefully give an insight into the potential molecular pathology of these forms of FTD.

2. Methods {#sec2}
==========

2.1. Ethics approval and consent to participate {#sec2.1}
-----------------------------------------------

Informed consent to participate in this study was given by all subjects or their caregivers. All samples were obtained from the Neurodegenerative Disease Unit of the Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, University of Milan (Milan, Italy).

2.2. CSF sample criteria, collection, and routine analysis {#sec2.2}
----------------------------------------------------------

Sample data is given in [Table 1](#tbl1){ref-type="table"}. Patients were recruited consecutively at the Neurodegenerative Disease Center of the Ospedale Policlinico between 2013 and 2015. The clinical workup included medical history, physical and neurological examination, screening laboratory tests, neurocognitive evaluation, lumbar puncture for Aβ, tau, and Ptau evaluation, and imaging. Cognitive functions were assessed by the clinical dementia rating (CDR), the mini mental state examination (MMSE), the frontal assessment battery (FAB), the Wisconsin Card Sorting Test (WCST), and the Tower of London test. The presence of significant vascular brain damage was excluded (Hachinski Ischemic Score \<4). The diagnosis of FTD was made according to consensus criteria ([@bib27]) and subsequent revisions ([@bib24], [@bib31]).Table 1Characteristics of AD patients, FTD patients, and controlsSubject detailsControls (n  =  15)AD patients (n  =  13)Sporadic FTD (n  =  16)C9orf72 FTD (n  =  7)GRN FTD (n  =  9)Gender (M/F)5:105:810:66:13:6Age, years (mean  ±  SD)61.0 ± 9.972.1  ±  6.871.8 ± 7.366.0  ±  8.063.5  ±  8.5APOE ε4 positive (%)13.3%69.2%56.2%14.2%22%CSF Biomarkers Aβ1-42 (pg/mL), median (IQR)895  (794--1132)446 (331.2--498.5)656 (552.3--741.8)839 (692--1141)841 (687--1314) T-tau (pg/mL), median (IQR)91  ±  (59-155)481 (264--666)688 (173--1114)291 (239--367)328 (268--440) P-tau (pg/mL), median (IQR)20.5  (17--28)84 (56--105)72 (28--107)68 (38--84)27(17--33)[^2]

Patients with AD (n = 13) all had abnormal CSF Aβ, t-tau, and p-tau levels, thus confirming the clinical diagnosis (G. [@bib23]) with an accuracy of about 90 % ([Table 1](#tbl1){ref-type="table"}), in accordance with more recent criteria ([@bib7]) ([@bib8]). Thirty-two patients with FTD were included: 7 *GRN* mutation carriers, 9 *C9orf72* expansion carriers, and 16 with sporadic disease.

Controls (n = 15) included patients undergone lumbar puncture on suspicion of neurological diseases that were disclosed with no evidence of neurological deficits and cognitive impairment. This cohort has previously been investigated for the effect of age on the proteins described in this study ([@bib15]). Only markers that did not show any significant change with age are presented in this study.

Clinical CSF was sampled according to a standard protocol ([@bib2]). CSF samples were obtained in polypropylene tubes by LP at the L4/L5 or L3/L4 interspace, centrifuged at 4 °C, and stored at  ≤ −30 °C until analysis. CSF cell counts, glucose, and proteins were determined. Routine analysis to exclude damage of the blood-brain barrier (BBB) included measurement of albumin by rate nephelometry and the intrathecal IgG production. The albumin quotient (CSF albumin/serum albumin) X 10^3^ and the IgG index (CSF albumin/serum albumin)/(CSF IgG/serum IgG) were calculated and samples without BBB damage were used in the study, which confirm that the proteins measured in this study are produced intrathecally and not leaking from the periphery ([@bib34]).

2.3. Aβ, tau, and Ptau measurement {#sec2.3}
----------------------------------

CSF tau concentration was determined using a sandwich enzyme-linked immunosorbent assay (ELISA) (INNOTEST hTAU-Ag, Fujirebio, Ghent, Belgium) specifically constructed to measure all tau isoforms irrespective of phosphorylation status. CSF Ptau was measured using a sandwich ELISA specifically detecting tau phosphorylated at amino acid 181 (INNOTEST PHOSPHO-TAU (181P), Fujirebio, Ghent, Belgium). Aβ levels were determined using a sandwich ELISA (INNOTEST ß- AMYLOID Fujirebio, Ghent, Belgium). Normal values of biomarkers were as follows: Aβ-\>550 pg/mL; tau  \< 375 pg/mL; and Ptau  \< 52 pg/mL ([@bib26]).

2.4. Targeted proteomics: MRM-based triple quadrupole mass spectral assay {#sec2.4}
-------------------------------------------------------------------------

A 54-protein MRM LC-MS/MS multiplex assay was originally designed to quantitate altered proteins that were identified from proteomic profiling of CSF from dementia patients as well as biomarker candidates suggested in the current literature at that time. Further detailed information regarding the selection and method development of the assay can be found in ([@bib15]). The initial analyses in this study were performed to identify proteins specific to the dementia type. Therefore, the FTD group comparison consisted of the *GRN*, *C9orf72* mutation carriers, and sporadic cases grouped together. Briefly, 20 nanograms of yeast enolase protein standard (Sigma, UK) and 10--50 pmols heavy labeled peptide standards (Thermo Scientific, UK) were added to 100 μL of CSF. CSF was freeze-dried and trypsin-digested as described previously ([@bib14]). A single 35 μL injection of each CSF digest was injected onto a Waters CORTECS UPLC C18 + Column, 90 Å, 1.6 μm, 3 mm  ×  100 mm column attached to a C18+ VanGuard precolumn. UPLC and MS tune conditions were performed as described previously ([@bib20]). QC runs of pooled CSF digests were run in triplicate at the start of the run and then every 10 injections. A CV within ±15% for each QC was considered acceptable. Chromatograms were analyzed using Waters Targetlynx software. Peptides were standardized by either using a spiked heavy labeled peptide or to a yeast enolase peptide. Absolute levels of pmols/100 μL CSF were obtained from standard curves.

2.5. Statistical analysis {#sec2.5}
-------------------------

Analyses included data QC for peptide performance (coefficient of variance), QC of sample preparation, and LC-MS/MS performance (yeast enolase). The normality of the variables was evaluated using D\'Agostino-Pearson\'s test. Non-normally distributed variables were transformed to Gaussian distribution by the operations listed in [Supplementary Data 2](#appsec1){ref-type="sec"}. The differences in protein expression between the groups were evaluated using one-factor ANOVA in conjunction with Tukey\'s multiple comparison post-test or Mann-Whitney U nonparametric test. Group age ranges were checked for significant difference using a Kruskal-Wallis with Dunns post-test of which no significant difference was confirmed.

3. Results {#sec3}
==========

3.1. Dementia grouped analysis {#sec3.1}
------------------------------

Only 2 proteins showed significant changes when samples were grouped according to dementia type ([Fig. 1](#fig1){ref-type="fig"}). Aβ-38 demonstrated a slight but not significant reduction in the mean of the AD group. However, the FTD group demonstrated a much greater and significant 2.6-fold reduction compared with controls (*p* \< 0.0001) and a significant 1.83-fold reduction compared to the AD group (*p* \< 0.001). Pro-orexin levels were statistically and significantly increased in both dementia groups with a 1.5-fold increase in FTD compared to controls (*p* \< 0.001) and a 1.87-fold increase in the AD group (*p* \< 0.0001). The AD group also demonstrated a significant 1.24-fold higher level of pro-orexin when compared to the FTD group (*p* \< 0.01). Soluble TREM2 (sTREM2) was included in the analysis and has previously been demonstrated to be elevated in AD using our assay ([@bib13]) and been shown to be elevated previously in FTD CSF by ELISA ([@bib29]). CSF levels of sTREM2 were significantly elevated in both the AD and FTD groups relative to the control group (*p* \< 0.0006). sTREM2 levels although elevated in both the AD and FTD groups were not different between both the neurodegenerative conditions. Correlation analysis with levels of routinely measured known disease CSF markers amyloid Aβ, tau, and Ptau did not demonstrate any relationship with pro-orexin or sTREM2 levels in CSF of either dementia. There was significant correlation between levels of Aβ-38 with Ptau in AD (r^2^ = 0.37 *p* \< 0.028) but not FTD. However, Aβ-38 did show a correlation with Aβ-42 in the FTD group (r^2^ = 0.38, *p* \< 0.001) ([Supplementary Data 1](#appsec1){ref-type="sec"}).Fig. 1Proteins differently expressed between AD and FTD. (A) a-beta-38 (untransformed data) and (B) pro-orexin are significantly altered between FTD from AD. (C) sTREM2 is elevated in both AD and FTD but there is no difference between the dementias. \* indicates *p* \< 0.05, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001 as determined by nonparametric Mann-Witney U analysis. Key: AD, Alzheimer\'s disease; FTD, frontotemporal dementia; sTREM2, soluble TREM2.

3.2. FTD subgroup analysis {#sec3.2}
--------------------------

The FTD group was subdivided into 2 groups consisting of those patients carrying *GRN* mutations and those with *C9orf72* expansions. Five proteins showed small but significant changes (*p* \< 0.04--0.01) between the *GRN* and *C9orf72* groups. The proteins in the *GRN* group which consistently showed a lower level relative to the C9orf72 group were apolipoprotein E, CD166, transthyretin, osteopontin, and cystatin C ([Fig. 2](#fig2){ref-type="fig"}).Fig. 2Proteins altered between the C9orf72 and GRN genetic forms of FTD. \* indicates *p* \< 0.05, \*\* *p* \< 0.01 as determined by nonparametric Mann-Witney U analysis. Key: FTD, frontotemporal dementia.

4. Discussion {#sec4}
=============

In previous work by our laboratory, we demonstrated that our method revealed significantly elevated proteins in the CSF of patients with AD relative to controls. Therefore, the aim of this study was to determine if our test was capable of detecting proteins altered between AD and FTD and if it was possible to see changes between FTD carrying different causal mutations. We found that only 2 proteins (pro-orexin and Aβ-38) differed in expression between the AD and FTD groups, whereas 5 proteins were altered between carriers of different mutations in FTD.

Analysis of pro-orexin levels revealed that this protein was slightly significantly elevated in AD compared to patients with FTD. Pro-orexin has been implicated previously in the pathogenesis of AD ([@bib17], [@bib19]) and in particular the hypothalamic dysfunction related to sleep impairment in AD ([@bib16]). Sleep disturbance can also be observed in FTD albeit not as commonly ([@bib22]). Consistent with this, we observed raised CSF pro-orexin in FTD compared with controls but to a lesser extent than AD ([@bib6]). It would be useful in future studies to correlate the presence of sleep symptoms with pro-orexin levels to see whether abnormalities in this protein can predict the presence of sleep disturbance.

The finding of reduced Aβ-38 levels specifically in the FTD group confirms previous observations by other groups ([@bib1], [@bib10]). However, the reason for this remains unclear. Although AD pathology can occasionally be seen as an additional finding at postmortem in patients with FTD, amyloid has not been implicated more generally in the pathophysiology of the FTD syndromes and Aβ-38 is not a plaque-associated form of Aβ. The levels of Aβ-42 and Aβ-40 overall are not altered to the degree as that seen for Aβ-38 in the FTD group. This indicates the effect on Aβ-38 is downstream of this mechanism and likely due to increased proteolysis. Aβ-38 can be cleaved by other enzymes such as neprilysin, insulin-degrading enzyme, endothelin-converting enzyme, angiotensin-converting enzyme, and the plasmin/uPA/tPA ([@bib36]), and potentially, Aβ-38 is a better substrate for these proteases than the other Aβ peptides. Interestingly, some other substrates of these proteases particularly neprilysin are feeding hormones. Alterations in feeding behavior are a known clinical feature in some forms of FTD ([@bib37]). It is possible that dysregulation of such a protease could be an initiating factor for some of the downstream pathological features in FTD. Neprilysin has been studied in the context of AD more for its potential as a plaque treatment ([@bib25]) but so far neprilysin has not been investigated in FTD. Another theoretical explanation for the more pronounced decrease of Aβ-38 in FTD could be γ-secretase modulation; decreased processivity of APP by γ-secretase could result in lower concentrations of shorter Aβ peptides, such as Aβ38 ([@bib5]), but this has to the best of our knowledge not been studied in FTD. We did attempt to look at proteins that could be altered just in sporadic FTD but no specific changes were observed apart from the previous pro-orexin and amyloid beta 38. Because of the heterogeneity of FTD pathology, this is unsurprising. Until further understanding of sporadic FTD at a molecular level is understood, it is hard to identify proteins that indicate specific subpathologies.

When subgrouping the FTD patients by genetic status, 5 proteins measured in the multiplex assay demonstrated a small but significant difference between the 2 genetic FTD groups, with lower levels in the *GRN* group compared with *C9orf72* group. Reduced expression of cystatin C has been described in response to systemic inflammation in dendritic cells ([@bib38]). This is consistent with previous work suggesting differential involvement of inflammatory pathways in *GRN*-related FTD compared with other subtypes of FTD ([@bib21]). However, the other proteins (osteopontin, CD166, transthyretin, apolipoprotein E) have also been postulated to be involved in the inflammatory response ([@bib3], [@bib32], [@bib35]) but this does not corroborate with *GRN* neuropathology which is found to be more profound than that observed in *C9orf72* pathology. One reasoning for this observation could be that these proteins maybe reduced in *GRN* CSF due to being sequestered at sites of inflammation in the brain. Further work should aim to replicate these measures in a larger FTD data set and understand further their exact role in FTD.

This study shows that a targeted MRM platform measuring multiple proteins are able to not only help to find proteins with altered expression between AD from FTD but can also identify differential involvement of proteins in FTD subtypes, consistent with the different pathophysiological mechanisms underlying these different forms of dementia. Limitations of this study include (1) the modest number of samples; and (2) the lack of pathological demonstration of the pathology, particularly in sporadic FTD, for which no biomarkers exist. As with discovery of all potential biomarkers, independent validation on separate and much larger cohorts will be required for any future clinical utilization. We believe this initial analysis and platform are a valuable proviso toward achieving this further validation in larger cohorts of clinically well-defined samples. Another strength of this platform is that other possible candidate biomarkers suggested from other studies and even possibly neprilysin from our own findings could be added to the panel.
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